Immunosuppressive drug therapy.

Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. J Am Soc Nephrol (2015) 0.81

TGF-β in tolerance, development and regulation of immunity. Cell Immunol (2015) 0.78

Use of pharmacogenomics in pediatric renal transplant recipients. Front Genet (2015) 0.78

Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. Am J Transplant (2016) 0.76

Nanoparticles and direct immunosuppression. Exp Biol Med (Maywood) (2016) 0.75

Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther (2017) 0.75

Multiplexed Nanoplasmonic Temporal Profiling of T-Cell Response under Immunomodulatory Agent Exposure. ACS Sens (2016) 0.75

Actively acquired tolerance of foreign cells. Nature (1953) 19.82

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65

HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42

Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40

Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79

Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32

Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13

Renal transplantation. N Engl J Med (1994) 3.33

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19

Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 3.12

The who, how and where of antigen presentation to B cells. Nat Rev Immunol (2009) 3.12

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05

Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol (2010) 3.01

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 2.67

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93

Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation (2012) 1.93

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90

Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci U S A (1992) 1.83

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med (2010) 1.80

Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev (2009) 1.72

Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev (2005) 1.60

Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation (1999) 1.59

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med (1985) 1.57

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant (2004) 1.50

Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant (2004) 1.42

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant (2008) 1.37

The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes. Nature (1989) 1.37

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant (2008) 1.34

Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation (2005) 1.32

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant (2005) 1.29

Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (2010) 1.15

Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med (1992) 1.14

Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med (2010) 1.11

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation (1999) 1.06

Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05

Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev (2006) 1.05

Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation (2009) 1.05

Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant (2007) 1.05

Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation (2010) 1.02

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol (2010) 1.01

Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation (1999) 1.01

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (2004) 1.01

A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation (2008) 0.99

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant (2009) 0.95

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation (2001) 0.95

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation (2004) 0.93

Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: implications for antigen presentation to cytotoxic T lymphocytes. Immunology (2004) 0.90

Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant (2002) 0.90

Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation (2004) 0.86

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation (2000) 0.85

Early corticosteroid withdrawal in recipients of renal allografts: a single-center report of ethnically diverse recipients and recipients of marginal deceased-donor kidneys. Transplantation (2012) 0.85

The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant (2011) 0.84

A novel model for antigen-dependent activation of normal human T cells. Transmembrane signaling by crosslinkage of the CD3/T cell receptor-alpha/beta complex with the cluster determinant 2 antigen. J Exp Med (1990) 0.83

Immunologic monitoring of the renal transplant recipient. Urol Clin North Am (1983) 0.78

Transplantation tolerance: fooling mother nature. Proc Natl Acad Sci U S A (1996) 0.78

Synergism between the CD3 antigen- and CD2 antigen-derived signals. Exploration at the level of induction of DNA-binding proteins and characterization of the inhibitory activity of cyclosporine. Transplantation (1993) 0.78

Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation. Nephrol Dial Transplant (2000) 0.76

Mycophenolate mofetil in kidney transplantation. Curr Opin Nephrol Hypertens (1996) 0.75

HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42

Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40

Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res (2004) 5.40

Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med (2005) 5.02

Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59

Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57

Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med (2007) 2.86

Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation (2002) 2.86

MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A (2009) 2.36

Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2007) 2.10

Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int (2003) 1.83

Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation (2014) 1.60

Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation (2008) 1.50

Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int (2004) 1.48

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation (2002) 1.33

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation (2003) 1.16

MicroRNAs: small RNAs with big effects. Transplantation (2010) 1.15

Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension (2012) 1.14

Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation (2005) 1.13

Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med (2014) 1.10

Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation (2007) 1.08

Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation (2004) 1.07

CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation (2003) 1.07

Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol (2006) 1.05

Transforming growth factor beta and progression of renal disease. Kidney Int Suppl (2003) 1.04

MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation (2012) 1.03

Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med (2006) 1.01

Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation (2010) 0.99

Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation (2012) 0.98

Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant (2010) 0.98

Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation (2003) 0.96

Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation (2008) 0.95

Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94

Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO-1-stained islets. Transplantation (2005) 0.94

Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation (2010) 0.90

Proapoptotic Bax is hyperexpressed in isolated human islets compared with antiapoptotic Bcl-2. Transplantation (2002) 0.90

Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation (2002) 0.89

Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation (2013) 0.88

Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev (2014) 0.88

Correlation between interleukin-15 and granzyme B expression and acute lung allograft rejection. Transpl Immunol (2004) 0.87

Circulating levels of 25-hydroxyvitamin D and acute cellular rejection in kidney allograft recipients. Transplantation (2014) 0.87

Early corticosteroid withdrawal in recipients of renal allografts: a single-center report of ethnically diverse recipients and recipients of marginal deceased-donor kidneys. Transplantation (2012) 0.85

Transcriptional profiling to assess the clinical status of kidney transplants. Nat Clin Pract Nephrol (2006) 0.85

Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation (2003) 0.85

On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-to-lot variations in MFI. Transplantation (2013) 0.85

Vesicoureteric reflux and reflux nephropathy as seen at a tertiary care adult nephrology service in India--an analysis of 86 patients. Ren Fail (2003) 0.82

Transforming growth factor beta and excess burden of renal disease. Trans Am Clin Climatol Assoc (2009) 0.82

Diannexin decreases inflammatory cell infiltration into the islet graft, reduces β-cell apoptosis, and improves early graft function. Transplantation (2010) 0.82

Noninvasive diagnosis of acute rejection of solid organ transplants. Front Biosci (2004) 0.81

Dendritic cells with TGF-β1 and IL-2 differentiate naive CD4+ T cells into alloantigen-specific and allograft protective Foxp3+ regulatory T cells. Transplantation (2012) 0.81

Noninvasive prognostication of polyomavirus BK virus-associated nephropathy. Transplantation (2013) 0.80

The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol (2006) 0.78

Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation (2012) 0.78

HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. Clin Transpl (2013) 0.78

Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure. Transplantation (2015) 0.77

Treating IgA nephropathy: quid novi? Discov Med (2014) 0.77

HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. Transplantation (2013) 0.76

Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int (2016) 0.76

Transplantation: Pump it up: conserving a precious resource? Nat Rev Nephrol (2009) 0.75

Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol (2014) 0.75

Transplantation: Personalizing induction therapy in kidney transplantation. Nat Rev Nephrol (2009) 0.75

Urinary-cell mRNA and acute kidney-transplant rejection. N Engl J Med (2013) 0.75

Excretion of anti-angiogenic proteins in patients with chronic allograft dysfunction. Nephrol Dial Transplant (2012) 0.75

Should hepatitis C virus infection be a contraindication to renal transplantation? Nat Clin Pract Nephrol (2008) 0.75

Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK VP1 virus in urine. Transplantation (2003) 0.75

The Nobel Prize-winning work of Ralph Steinman (1943-2011) and its relevance to transplantation. Transplantation (2013) 0.75

Transplantation: a report of progress. Transplantation (2010) 0.75

Transplantation: a report of progress. Transplantation (2013) 0.75

Excellent outcomes with expanded criteria donor kidneys: the role of the recipient's age. Clin Transpl (2013) 0.75

Optimal modes and targets of gene therapy in transplantation. Immunol Rev (2003) 0.75

Transplantation: a report of progress. Transplantation (2008) 0.75

Mean arterial blood pressure while awaiting kidney transplantation is associated with the risk of primary nonfunction. Transplantation (2012) 0.75

Urine injury biomarkers are not associated with kidney transplant failure. Transplantation (2019) 0.75